Medtronic To Compare Endeavor To Boston Scientific’s Taxus In New Trial
This article was originally published in The Gray Sheet
Executive Summary
Medtronic's addition of a fourth clinical trial to support its Endeavor AVT-578-eluting coronary stent is unlikely to delay the PMA filing past the previously stated target of summer 2005, the company asserts
You may also be interested in...
Medtronic DES study
Firm announces the first patient implant was performed April 11 in its 1,548-patient, randomized trial to support the Endeavor ABT-578-eluting stent PMA. The study, named ENDEAVOR IV, will compare Endeavor head-to-head against Boston Scientific's Taxus paclitaxel-eluting stent by measuring target vessel failure at nine months as the primary endpoint and major adverse cardiac events at 30 days as a secondary endpoint (1"The Gray Sheet" Feb. 28, 2005, p. 19)...
Medtronic DES study
Firm announces the first patient implant was performed April 11 in its 1,548-patient, randomized trial to support the Endeavor ABT-578-eluting stent PMA. The study, named ENDEAVOR IV, will compare Endeavor head-to-head against Boston Scientific's Taxus paclitaxel-eluting stent by measuring target vessel failure at nine months as the primary endpoint and major adverse cardiac events at 30 days as a secondary endpoint (1"The Gray Sheet" Feb. 28, 2005, p. 19)...
Boston Scientific Taxus U.S. Market Share Recoups From 56% Low On Recall
Boston Scientific's average Taxus drug-eluting stent sales of $7.4 mil. a day in the U.S. for the week ended Aug. 27 represents a return to 70% market share after dipping to 56% in the wake of a July recall, the firm says